Psyence is a listed life science biotechnology company pioneering the use of natural psilocybin to heal psychological trauma and the diagnosable disorders that can result: anxiety, depression, PTSD, stress, grief and bereavement. We have a focus on these conditions in the context of palliative care. We are focused on the scientific research and development of psilocybin medical products for research institutions, clinics and regulatory-compliant psilocybin containing products. We are also developing nutraceutical products for depression, acute anxiety and sleep disorders.Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and OTCQB® Venture Market in the US (OTCQB:PSYGF) and our diversified business has a global footprint with operations in multiple legal jurisdictions. We operate one of the first federally licensed commercial psilocybin cultivation and production facilities in the world in Southern Africa. For more information: www.psyence.com

MindHealth Biomed is a Canadian based health sciences organisation that is focused on cultivation, manufacturing and distribution of medical grade health products for medical research, psychedelic health therapy and nutraceutical microdose. MindHealth Biomed merged with Psyence to form Psyencr Group Inc. which listed in January 2021.

Financial consultant on a variety of projects and financial roles. Clients included Royal Bank of Scotland Asset Management, Bank of New York Mellon, IntercontinentalExchange and Coface.